Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Manufacturing, characterization and anti-tumor activity of allogeneic CD19-CAR cytokine-induced killer (CIK) cells engineered with non-viral sleeping beauty transposon system and armored with IL-18
    Meeting Abstract

    Contreras-Ruiz, L.; Pace, B.; Kohnke, D. E.; Viruet, L.; Adams, M.; Krisko, J. F.; Leesnitzer, N.; Velie, M.; Tettamanti, S.; Pisani, I.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • ASC2ESCALATE: A US phase 2, open-label, single-arm, dose-escalation study of asciminib (ASC) monotherapy in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) as second-line (2L) and first-line (1L) treatment
    Meeting Abstract

    Atallah, E. L.; Mauro, M.; Sasaki, K.; Levy, M.; Koller, P. B.; Yang, D.; Laine, D.; Sabo, J.; Gu, E.; Cortes, J.
    Blood (2023)

    Fulltext@MSK | Save
  • Revumenib maintenance therapy following revumenib-induced remission and transplant
    Meeting Abstract

    Zucenka, A.; Issa, G. C.; Arellano, M.; Khazal, S.; Khera, N.; Stock, W.; Cuglievan, B.; Gu, Y.; Nguyen, H. V.; Smith, A. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Preliminary results from a phase 1 dose escalation study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, administered as an oral monotherapy in patients with advanced hematologic malignancies
    Meeting Abstract

    DiNardo, C. D.; Savona, M. R.; Kishtagari, A.; Fathi, A. T.; Bhalla, K. N.; Agresta, S.; Reilly, S.; Almon, C.; Hentemann, M.; Hickman, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical practice gaps in managing patients with myelofibrosis: Comparison of healthcare professional and expert treatment choices provided to an online decision support tool
    Meeting Abstract

    Topping, R. P.; Bose, P.; Mascarenhas, J.; Rampal, R. K.; Stein, B. L.; Quill, T. A.; Mesa, R. A.
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in patients with JAK inhibitor-naive myelofibrosis and moderate thrombocytopenia (XPORT-MF-044)
    Meeting Abstract

    Scandura, J. M.; Gerds, A. T.; Ritchie, E. K.; Wang, X.; Kye, S.; Rampal, R. K.
    Blood (2023)

    Fulltext@MSK | Save
  • Ivosidenib for patients with clonal cytopenia of undetermined significance and mutations in IDH1
    Meeting Abstract

    Petrone, G.; Stein, E. M.; Bolton, K. L.
    Blood (2023)

    Fulltext@MSK | Save
  • Potent and target specific cytotoxicity of PRAME TCR mimic CAR T cells in KMT2A-rearranged AML patient-derived xenograft model
    Meeting Abstract

    Kirkey, D. C.; Robinson, L.; Hylkema, T.; Loeb, A.; Ries, R. E.; McKay, C.; Root, C.; Pardo, L.; Loeb, K. R.; Le, Q.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1b trial of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia
    Meeting Abstract

    Gangat, N.; Foran, J. M.; Halpern, A. B.; Rampal, R. K.; Novikov, N.; Buch, A.; Pelletier, O.; Savage, W.; Tefferi, A.
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of symptom benefit and transfusion response on survival in myelofibrosis patients treated with pacritinib: PERSIST-2 landmark survival analysis
    Meeting Abstract

    Ajufo, H.; Bewersdorf, J. P.; Harrison, C. N.; Palandri, F.; Mascarenhas, J.; Palmer, J.; Gerds, A. T.; Kiladjian, J. J.; Buckley, S.; Derkach, A.; more...
    Blood (2023)

    Fulltext@MSK | Save